Related Experiment Video
Updated: May 25, 2026
Cerenkov Luminescence Imaging (CLI) for Cancer Therapy Monitoring
Published on: November 13, 2012
GCPII imaging and cancer.
1Russell H. Morgan Department of Radiology and Radiological Science, Johns Hopkins Medical School, Baltimore, MD 21231, USA.
Glutamate carboxypeptidase II (GCPII), also known as prostate-specific membrane antigen (PSMA), is a promising target for prostate cancer imaging and therapy. Its expression in tumor neovasculature suggests broader potential for other cancers.
Area of Science:
- Biochemistry
- Oncology
- Medical Imaging
Background:
- Glutamate carboxypeptidase II (GCPII) is expressed in the central nervous system.
- In the periphery, GCPII is known as prostate-specific membrane antigen (PSMA).
- PSMA is increasingly recognized for its role in cancer biology.
Purpose of the Study:
- To provide an overview of GCPII/PSMA in the context of cancer.
- To discuss the application of PSMA-targeting agents for prostate cancer imaging.
- To explore the use of PSMA-targeting agents for prostate cancer therapy.
Main Methods:
- Review of existing literature on GCPII/PSMA.
- Analysis of PSMA expression in various cancers.
- Discussion of diverse PSMA-targeting agents for diagnostic and therapeutic applications.
Main Results:
- GCPII and PSMA are the same enzyme with distinct localization.
- PSMA is a validated target for prostate cancer imaging and therapy.
- PSMA expression in tumor neovasculature indicates potential utility beyond prostate cancer.
Conclusions:
- PSMA is a significant biomarker and therapeutic target in oncology.
- PSMA-based imaging and therapy offer a versatile platform for cancer management.
- Further research into PSMA's role in other malignancies is warranted.
More Related Videos
10:28Gene Regulation and Targeted Therapy in Gastric Cancer Peritoneal Metastasis: Radiological Findings from Dual Energy CT and PET/CT
Published on: January 22, 2018
06:49Orthotopic Implantation of Patient-Derived Cancer Cells in Mice Recapitulates Advanced Colorectal Cancer
Published on: February 10, 2023
